Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Bal Pharma
Small Cap•986 Employees•IPO 1995
Current Price
₹74.72
-0.56 (-0.74%)Updated
Today's Range
₹68.60
₹75.90
₹74.72
52 Week Range
52W Low₹65.70
52W High₹128.74
₹74.72
Downside13.73%
Upside72.30%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹121 Cr
Market Cap
Total market value of companyP/E Ratio
16.89
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.71
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹4.40
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
8.86%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
10.10%
ROCE
Return on Capital Employed. >15% is goodNet Margin
2.43%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
6.14%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-11.40%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-19.20%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
1.94
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹48.63
Book Value
Net asset value per shareDividend Yield
1.58%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
50.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Promoter holding at 50.9% indicates strong management confidence.
- •Offers a decent dividend yield of 1.50% for income-focused investors.
Weaknesses
5 points- •High debt-to-equity ratio of 1.94 indicates significant financial leverage.
- •Latest quarterly sales declined 11.40% and net profit by 19.20%.
Opportunities
5 points- •Stable demand and growth trends in the pharmaceutical sector.
- •Small market cap (1271.28 Cr) offers potential for market share expansion.
Threats
4 points- •Highly competitive pharmaceutical sector with larger peers posing significant threat.
- •Subject to stringent and evolving regulatory policies impacting product approvals.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹92.15 | +₹17.43 | +23.32% |
| R3 | ₹84.85 | +₹10.13 | +13.55% |
| R2 | ₹80.37 | +₹5.65 | +7.57% |
| R1 | ₹77.55 | +₹2.83 | +3.78% |
| PIVOT | ₹73.07 | -1.65 | -2.20% |
| CURRENT | ₹74.72 | - | - |
| S1 | ₹55.65 | -₹19.07 | -25.53% |
| S2 | ₹62.95 | -₹11.77 | -15.76% |
| S3 | ₹65.77 | -₹8.95 | -11.97% |
| S4 | ₹70.25 | -₹4.47 | -5.99% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+59.5% vs avg
0.22L
(02 Mar 2026)Delivery %-23.4% vs avg
41.2%
(02 Mar 2026)Avg Volume (20D)20-day average
0.14L
(03 Feb - 02 Mar)Avg Delivery %Trend ↓
64.6%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Par Drugs & Chemicals Ltd
31.60 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Krebs Biochemicals & Industries Ltd |
 Mangalam Drugs and Organics Ltd |
 Par Drugs & Chemicals Ltd |
 Sun Pharmaceutical Industries Ltd |
 Vaishali Pharma Ltd |
About
Bal Pharma Ltd
Bal Pharma Limited is a pharmaceutical company headquartered in Bengaluru, India, that manufactures and markets a diverse range of pharmaceutical formulations and active pharmaceutical ingredients (APIs) both domestically and internationally. Their product portfolio caters to a broad spectrum of therapeutic areas and consumer needs.
The company's offerings include a wide array of prescription drugs, generic medications, over-the-counter (OTC) products, and intravenous infusion products. This encompasses various therapeutic categories such as anti-infectives, pain management solutions, respiratory care medications, and women's health products, marketed under various brand names including Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel. They also produce diabetic care products (Diabend and Diabend M Group), herbal/ayurvedic preparations for conditions like prostate enlargement, renal calculi, and infertility (Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin), and products addressing cardiovascular health, skin care, and bone health (Secremet and Servace brands).
Beyond finished formulations, Bal Pharma is a significant player in the API market, providing a wide array of active ingredients for numerous therapeutic applications. These APIs support the production of medications targeting conditions such as allergies, inflammation, diabetes, neurological disorders, urinary issues, and acne. The company manufactures diverse dosage forms including tablets, capsules, syrups, suspensions, ophthalmic preparations, creams, and ointments.
Furthermore, Bal Pharma's expertise extends to the treatment of gastrointestinal disorders and conditions like piles, fistula, and constipation. The company's international reach is substantial, with exports spanning approximately 30 countries. Established in 1987, Bal Pharma has grown to become a prominent player in the Indian and global pharmaceutical landscape.
COMPANY FACTS - BALPHARMA
Registered Address
5th floor, Lakshminarayan Complex,, 10/1, Palace Road,
Bangalore
KARNATAKA
IN
Tel: 918041379500
Website:https://www.balpharma.com/
Investor Relations:http://www.balpharma.com/finance
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 986
IPO Date: 01/02/1995
MANAGEMENT - BALPHARMA
Mr. Akash Mathur
Chief Executive Officer
Mr. Abdul Basith
Compliance Officer, Company Secretary
Shailesh Siroya
Managing Director, Executive Director
Sarika Bhandari
Additional Director
Mr. Jatish Sheth
Additional Non-Executive Director
Ms. Nicola Neeladri
Independent Director
Investor Questions Answered
Bal Pharma Ltd (BALPHARMA) Stock FAQs
Get answers to the most common questions about Bal Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Bal Pharma Ltd (BALPHARMA) is ₹74.72. Today, the stock has declined by ₹0.56 (0.74%), trading in a range of ₹68.6 to ₹75.9. The stock opened at ₹72.1 with a trading volume of 21,568 shares.
Bal Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹121 crores, P/E ratio of 16.89, ROE of 8.86%, and ROCE of 10.10%. The dividend yield stands at 1.58%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Bal Pharma Ltd (BALPHARMA) is ₹128.74, while the 52-week low is ₹65.7. Currently trading at ₹74.72, the stock is 14.3% away from its 52-week low and 42.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Bal Pharma Ltd stock at ₹74.72 depends on multiple factors. The stock is currently trading with a P/E ratio of 16.89 and P/B ratio of N/A. Today's performance shows a loss of 0.74%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Bal Pharma Ltd offers a dividend yield of 1.58%, which means for every ₹100 invested at the current price of ₹74.72, you can expect to receive approximately ₹1.58 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Bal Pharma Ltd's key financial metrics include: P/E Ratio: 16.89, P/B Ratio: N/A, ROE: 8.86%, ROCE: 10.10%, Dividend Yield: 1.58%, EPS: ₹4.40, Book Value: ₹48.63, Debt-to-Equity: 1.94, and Current Ratio: N/A. The company's market cap stands at ₹121 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Bal Pharma Ltd stock opened at ₹72.1 and is currently trading at ₹74.72, showing a decline of ₹0.56 (0.74%). The intraday high is ₹75.9 and low is ₹68.6. The trading volume stands at 21,568 shares, indicating moderate market participation today.
Bal Pharma Ltd has a Price-to-Earnings (P/E) ratio of 16.89, which means investors are willing to pay ₹16.89 for every ₹1 of earnings. With an EPS of ₹4.40, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Bal Pharma Ltd has a market capitalization of ₹121 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹74.72) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Bal Pharma Ltd has a book value of ₹48.63 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹74.72, which is 53.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Bal Pharma Ltd has a Return on Equity (ROE) of 8.86% and Return on Capital Employed (ROCE) of 10.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Bal Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Bal Pharma Ltd has a debt-to-equity ratio of 1.94, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 1 suggests the company uses more debt than equity for financing. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Bal Pharma Ltd has an Earnings Per Share (EPS) of ₹4.40, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹74.72 and P/E ratio of 16.89, investors are paying 16.89 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Bal Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Bal Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Bal Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (16.89), ROE (8.86%), debt-to-equity (1.94), and growth rates. 2) Technical Analysis - Check 52-week range (₹65.70 - ₹128.74), moving averages, and chart patterns. 3) Valuation - Compare current price (₹74.72) with book value (₹48.63) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Bal Pharma Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹74.72 is 647x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Bal Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹65.70 - ₹128.74). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 1.94 indicates leverage. 4) Liquidity Risk - Based on trading volume of 21,568 shares. 5) Valuation Risk - P/E of 16.89 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Bal Pharma Ltd operates in the industry with key metrics: P/E ratio of 16.89, ROE of 8.86%, market cap of ₹121 crores, and dividend yield of 1.58%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 1.94), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Bal Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹74.72, with a 52-week range of ₹65.70 to ₹128.74. Based on fundamentals like P/E (16.89), ROE (8.86%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Bal Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹74.72. 2) Fundamental Deterioration - Declining ROE (currently 8.86%), increasing debt (D/E: 1.94), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Bal Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.58%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu